Pharmaceutical formulations of desmopressin
First Claim
1. A solid orodispersible pharmaceutical dosage form of desmopressin acetate, comprising desmopressin acetate in an open matrix network carrying the desmopressin acetate, wherein the open matrix network comprises a water-soluble or water-dispersible carrier material inert to the desmopressin acetate that comprises gelatin, and wherein the dosage form disintegrates in the mouth within 10 seconds.
0 Assignments
0 Petitions
Accused Products
Abstract
Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
142 Citations
18 Claims
- 1. A solid orodispersible pharmaceutical dosage form of desmopressin acetate, comprising desmopressin acetate in an open matrix network carrying the desmopressin acetate, wherein the open matrix network comprises a water-soluble or water-dispersible carrier material inert to the desmopressin acetate that comprises gelatin, and wherein the dosage form disintegrates in the mouth within 10 seconds.
-
2. The dosage form of clam 1, wherein the gelatin comprises fish gelatin.
- 10. A process for preparing a solid orodispersible pharmaceutical dosage form of desmopressin acetate which disintegrates in the mouth within 10 seconds, comprising sublimating solvent from a composition comprising desmopressin acetate and a solution of a water-soluble or water-dispersible carrier material inert to the desmopressin acetate that comprises gelatin in a solvent.
-
11. The process of clam 10, wherein the gelatin comprises fish gelatin.
-
18. The method of clam 17, wherein the subject is in need of voiding postponement and/or the treatment of incontinence, primary nocturnal enuresis (PNE), nocturia, and/or central diabetes insipidus.
Specification